Located in Milan, Italy, the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) was created in 1995 as a joint venture between the Telethon Foundation and Ospedale San Raffaele (OSR) with the mission to perform cutting-edge research in gene and cell therapy and to translate its results into therapeutic advances, focusing on genetic diseases. SR-Tiget is fully integrated within OSR and has dedicated infrastructures to support high-quality preclinical studies and proof-of-concept clinical trials.

A postdoctoral research fellow position is available in the laboratory of Dr. A. Mortellaro & Prof. A. Aiuti. We are looking for a highly motivated individual to study the immunological and molecular basis of adenosine deaminase 2 deficiency, a newly discovered autoinflammatory syndrome, and implement gene therapy and editing approaches as promising strategies to treat the affected patients. Collectively, these studies will contribute to advance our knowledge of autoinflammatory disorders and improve patients’ care.

Job Requirements:

  • Ph.D. in Immunology, Cellular and Molecular Biology or related areas
  • Solid knowledge in Immunology and Innate Immunity
  • A track record of accomplishments
  • Demonstrated technical independence with tissue culture, molecular and biochemical techniques, and flow cytometry. Ability in transgenic/knock-out mouse-related work is a plus.
  • Ability in taking the initiative and work independently is essential
  • Strong interpersonal and communicative skills are indispensable
  • Proficiency in spoken and written English.

Interested candidates should send their curriculum vitae, a short statement of research interests and full contact information of three referees to:

Alessandra Mortellaro
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
IRCCS San Raffaele Institute
Via Olgettina, 58, 20132 Milan, Italy
Phone +39 02 2643 5326
mortellaro.alessandra@hsr.it

We regret that only shortlisted candidates will be contacted

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.